LEADER 01953oam  2200457   450 
001 9910704729003321
005 20131028114013.0
035   $a(CKB)5470000002444437
035   $a(OCoLC)855764785
035   $a(EXLCZ)995470000002444437
100   $a20130814d2013      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aReview of the proposed generic drug and biosimilars user fees and further examination of drug shortages $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012
210  1$aWashington :$cU.S. Government Printing Office,$d2013.
215   $a1 online resource (iv, 194 pages) $cillustrations
300   $aTitle from title screen (viewed on Aug. 14, 2013).
300   $aPaper version available for sale by the Superintendent of Documents, U.S. Government Printing Office.
300   $a"Serial no. 112-114."
320   $aIncludes bibliographical references.
517   $aReview of the proposed generic drug and biosimilars user fees and further examination of drug shortages 
606   $aDrug approval$zUnited States
606   $aGeneric drugs$xGovernment policy$zUnited States
606   $aBiologicals$xGovernment policy$zUnited States
606   $aDrug accessibility$zUnited States
606   $aFees, Administrative$zUnited States
615  0$aDrug approval
615  0$aGeneric drugs$xGovernment policy
615  0$aBiologicals$xGovernment policy
615  0$aDrug accessibility
615  0$aFees, Administrative
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910704729003321
996   $aReview of the proposed generic drug and biosimilars user fees and further examination of drug shortages$93535166
997   $aUNINA